Skip to main navigation Skip to search Skip to main content

Clodronate in myelofibrosis: A case report

  • Paul Froom
  • , Irit Elmalah
  • , Andrei Braester
  • , Ester Aghai
  • , Miriam Quitt
  • Carmel Medical Center

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

A 59-year-old man had well-documented agnogenic myeloid metaplasia (AMM) with pancytopenia. Frequent blood transfusions were required over a 10-month period. Androgen therapy was not beneficial and treatment with interferon resulted in severe thrombocytopenia with no decrease in transfusion requirements. Treatment with clodronate at a daily oral dose of 30 mg/kg resulted in a marked decrease in bone marrow fibrosis, and gradual normalization of blood counts over an 8-month period. He has been transfusion independent for the last 33 months. We support the findings of a previous case report that oral bisphosphonate therapy may be of value in patients with AMM.

Original languageEnglish
Pages (from-to)115-116
Number of pages2
JournalAmerican Journal of the Medical Sciences
Volume323
Issue number2
DOIs
StatePublished - Feb 2002
Externally publishedYes

Keywords

  • Agnogenic myeloid metaplasia (AMM)
  • Bisphosphonates

Fingerprint

Dive into the research topics of 'Clodronate in myelofibrosis: A case report'. Together they form a unique fingerprint.

Cite this